Access the full text.
Sign up today, get DeepDyve free for 14 days.
F. Petrelli, S. Barni, G. Bregni, F. Braud, S. Cosimo (2016)
Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trialsBreast Cancer Research and Treatment, 160
Z. Dong, J. Meller, P. Succop, Jiang Wang, K. Wikenheiser-Brokamp, S. Starnes, Sha Lu (2014)
Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cellsInternational Journal of Oncology, 45
Shengshui Xu, Cheng Chen, Weixing Wang, Shun-rong Huang, Jia Yu, Xiaoyan Chen (2010)
Crucial role of group IIA phospholipase A2 in pancreatitis-associated adrenal injury in acute necrotizing pancreatitis.Pathology, research and practice, 206 2
Vesna Brglez, G. Lambeau, T. Petan (2014)
Secreted phospholipases A2 in cancer: diverse mechanisms of action.Biochimie, 107 Pt A
S. Pedada, N. Yarla, P. Tambade, B. Dhananjaya, A. Bishayee, K. Arunasree, G. Philip, Gangappa Dharmapuri, G. Aliev, Swathi Putta, G. Rangaiah (2016)
Synthesis of new secretory phospholipase A2-inhibitory indole containing isoxazole derivatives as anti-inflammatory and anticancer agents.European journal of medicinal chemistry, 112
Hong‐Lin He, Ying‐En Lee, Y. Shiue, Sung-Wei Lee, Li‐Ching Lin, Tzu-Ju Chen, Ting-feng Wu, Chien-Feng Li (2015)
PLA2G2A overexpression is associated with poor therapeutic response and inferior outcome in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapyHistopathology, 66
Jessica Yu, D. Mauchley, Howard Li, Xianzhong Meng, R. Nemenoff, D. Fullerton, M. Weyant (2012)
Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo.The Journal of thoracic and cardiovascular surgery, 144 5
G. Lambeau, M. Gelb (2008)
Biochemistry and physiology of mammalian secreted phospholipases A2.Annual review of biochemistry, 77
M. Menschikowski, Albert Hagelgans, U. Schuler, Susanne Froeschke, A. Rosner, G. Siegert (2013)
Plasma Levels of Phospholipase A2-IIA in Patients with Different Types of Malignancies: Prognosis and Association with Inflammatory and Coagulation BiomarkersPathology & Oncology Research, 19
M. Wang, Fengjie Hao, J. Wang, W. Xiao (2014)
Group IIa secretory phospholipase A2 (sPLA2IIa) and progression in patients with lung cancer.European review for medical and pharmacological sciences, 18 18
Houman Pourhassan, Gael Clergeaud, A. Hansen, Ragnhild ϕstrem, F. Fliedner, F. Melander, O. Nielsen, C. O’Sullivan, A. Kjær, T. Andresen (2017)
Revisiting the use of sPLA2‐sensitive liposomes in cancer therapyJournal of Controlled Release, 261
Jingkun Qu, Xixi Zhao, Jizhao Wang, Chao Liu, Yuchen Sun, H. Cai, Jianlin Liu (2018)
Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer.Oncology letters, 15 4
F. Fouladi, K. Steffen, S. Mallik (2017)
Enzyme-Responsive Liposomes for the Delivery of Anticancer Drugs.Bioconjugate chemistry, 28 4
F. Bray, J. Ferlay, I. Soerjomataram, R. Siegel, Lindsey Torre, A. Jemal (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA: A Cancer Journal for Clinicians, 68
A. Nicolini, P. Ferrari, M. Duffy (2017)
Prognostic and predictive biomarkers in breast cancer: Past, present and future.Seminars in cancer biology, 52 Pt 1
E. Kupert, Marshall Anderson, Yin Liu, P. Succop, L. Levin, Jiang Wang, K. Wikenheiser-Brokamp, Pingping Chen, S. Pinney, Trudy Macdonald, Z. Dong, S. Starnes, Sha Lu (2011)
Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodulesBMC Cancer, 11
A. Halpern, Patrick Kohtz, Jessica Rove, L. Ao, Xianzhong Meng, D. Fullerton, M. Weyant (2019)
Inhibition of secretory phospholipase A2 IIa attenuates prostaglandin E2-induced invasiveness in lung adenocarcinomaMolecular and Cellular Biochemistry, 456
L. Oleksowicz, Yin Liu, R. Bracken, K. Gaitonde, Barbara Burke, P. Succop, L. Levin, Z. Dong, Sha Lu (2012)
Secretory phospholipase A2‐IIa is a target gene of the HER/HER2‐elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancerThe Prostate, 72
Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours
R. Østrem, L. Parhamifar, Houman Pourhassan, Gael Clergeaud, O. Nielsen, A. Kjær, A. Hansen, T. Andresen (2017)
Secretory phospholipase A2 responsive liposomes exhibit a potent anti-neoplastic effect in vitro, but induce unforeseen severe toxicity in vivo.Journal of controlled release : official journal of the Controlled Release Society, 262
F. Mannello, Wenyi Qin, Weizhu Zhu, L. Fabbri, G. Tonti, E. Sauter (2008)
Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2Breast Cancer Research and Treatment, 111
Sungmin Lee, Daehoon Kim, Jihoon Kang, EunGi Kim, Wanyeon Kim, Hyesook Youn, B. Youn (2017)
Surfactant Protein B Suppresses Lung Cancer Progression by Inhibiting Secretory Phospholipase A2 Activity and Arachidonic Acid ProductionCellular Physiology and Biochemistry, 42
Vesna Brglez, A. Pucer, J. Pungerčar, G. Lambeau, T. Petan (2014)
Secreted phospholipases A₂are differentially expressed and epigenetically silenced in human breast cancer cells.Biochemical and biophysical research communications, 445 1
A. Dijk, P. Krijnen, R. Vermond, Amanda Pronk, M. Spreeuwenberg, Frans Visser, Richard Berney, Walter Paulus, C. Hack, Florine Milligen, Hans Niessen (2009)
Inhibition of type 2A secretory phospholipase A2 reduces death of cardiomyocytes in acute myocardial infarctionApoptosis, 14
Secreted phospholipase A2 group IIa (sPLA2-IIa) has been shown to promote tumor genesis and cell proliferation. The properties of this group of enzymes are utilized in liposomal drug delivery of chemotherapy. sPLA2-IIa is also under investigation as a possible treatment target in itself, and as a prognostic marker. The expression of sPLA2-IIa in breast cancer has not been examined extensively, and never using immunohistochemistry. We sought to investigate the expression of sPLA2-IIa in a cohort of advanced breast cancer patients with correlation to known clinicopathologic risk factors and survival. Material from 525 breast cancer patients (426 primary tumors and 99 metastases or local recurrences) was examined for sPLA2-IIa expression using immunohistochemistry. Out of these, 262 showed expression of sPLA2-IIa. We found that there was no correlation to clinicopathologic characteristics, and no impact of sPLA2-IIa expression on prognosis. However, we found that a large proportion of patients in our study had high levels of sPLA2-IIa expression, and that sPLA2-IIa was equally expressed in primary tumors and metastases. These findings may be significant in the future development of liposomal drug delivery or targeted sPLA2-IIa treatment.
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Jan 24, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.